Application of 40% Trichloroacetic Acid in the Treatment for Recurrent Genital Herpes

Background:Genital herpes is one of the common sexually transmitted diseases affect more than
400,000,000 individuals worldwide.The disease characterized by relapse and remission courses
and caused by herpes simplex virus (HSV) type 2.However, satisfactory curative agents are still
unavailable.
Objectives:This study intends to evaluate the benefit of 40% Trichloroacetic acid (TCA) in the
management of recurrent genital herpes lesions of the external male genitalia and to detect the
recurrence rate during this therapeutic regimen.
Materials and methods:The study extended between 1998 to 2017 and totally, 175 patients
with active disease were treated by oral administration of acyclovir 400mg 5 times per day for 5
days. Only 99 patients were followed up for one year and enrolled in the study. After 2 weeks, the
recurrent cases were subjected to the chemical peeling using topical application of 40% TCA at the
site of reactivation.
Results:The most affected age group was 40-50 years (n=45, 45.45%). The neck of the penis was
the most affected site (n=56, 56.57%).Forty patients had only one recurrence during a one-year
follow-up after treatment with 40% TCA.
Conclusion:This study approved the clinical effectiveness of the topical application of 40% TCA
in reducing the recurrence rate of the genital herpes lesions.We recommend using this chemical
peeling method in the treatment of patients with genital herpe

Keywords:

Recurrent genital herpes simplex virus (RGHSV)

Herpes Simplex Virus (HSV)

Trichloroacetic acid (TCA)

Acyclovir (ACV)

PDF (474 K)

[1] Jean L. Bolognia, Joseph L. Jorizzo, and Julie V. Schaf-
fer. Dermatology.Elsevier Doyma, 3rd Edition, 2012.
[2] F. Xuet al.Trends in herpes simplex virus type 1
and type 2 seroprevalence in the united states.Jama,
296(8):964–973, 2006.
[3] O. Kortekangas-Savolainen, E. Orhanen, T. Puodinketo,
and T. Vuorinen.Epidemiology of genital herpes sim-
plex virus type 1 and 2 infections in southwestern finland
during a 10-year period (20032012).Sex. Transm. Dis.,
41(4):268–271, 2014.
[4] R. Gupta, T. Warren, and A. Wald.Genital herpes.
Lancet, 370(9605):2127–2137, 2007.
[5] A. Wald, M. Ericsson, E. Krantz, S. Selke, and L. Corey.
Oral shedding of herpes simplex virus type 2.Sex.
Transm. Infect., 80(4):272–276, 2004.
[6] K. E. Market al.Rapidly cleared episodes of herpes
simplex virus reactivation in immunocompetent adults.
J. Infect. Dis., 198(8):1141–1149, 2008.
[7] D. T. Fleminget al.Herpes simplex virus type 2 in
the united states,1976 to 1994.N. Engl. J. Med.,
337(16):1105–1111, 1997.
[8] L. Corey, H. G. Adams, Z. A. Brown, and K. K. Holmes.
Genital herpes simplex virus infections: clinical manifes-
tations, course, and complications.Ann. Intern. Med.,
98(6):958–972, 1983.
[9] D. W. Kimberlin and D. J. Rouse.Genital herpes.N.
Engl. J. Med., 350(19):1970–1977, 2004.
[10] A. Birkmann and H. Zimmermann. Hsv antiviralscurrent
and future treatment options.Curr. Opin. Virol., 18:9–
13, 2016.
[11] D. Baker and D. Eisen.Valacyclovir for prevention
of recurrent herpes labialis:2 double-blind,placebo-
controlled studies.Cutis, 71(3):239–242, 2003.
[12] J. F. Rooneyet al. Oral acyclovir to suppress frequently
recurrentherpeslabialis:adouble-blind,placebo-
controlledtrial.Ann.Intern.Med.,118(4):268–272,
1993.
[13] G. Gabriel and R. N. Thin.Treatment of anogenital
warts. comparison of trichloracetic acid and podophyllin
versuspodophyllinalone.Sex.Transm.Infect.,
59(2):124–126, 1983.
[14] A. N. Abdullah, M. Walzman, and A. Wade. Treatment
of external genital warts comparing cryotherapy (liquid
nitrogen) and trichloroacetic acid.Sex. Transm. Dis.,
20(6):344–345, 1993.
[15] D.B.Schwartz,M.D.Greenberg,Y.Daoud,and
R.Reid.Genitalcondylomasinpregnancy:useof
trichloroacetic acid and laser therapy.Am. J. Obstet.
Gynecol, 158(6):1407–1416, 1988.
[16] M. J. Godley, C. S. Bradbeer, M. Gellan, and R. N.
Thin. Cryotherapy compared with trichloroacetic acid in
treating genital warts.Sex. Transm. Infect., 63(6):390–
392, 1987.
[17] R. Romero and I. Nygaard. Cdc updates guidelines for
treating sexually transmitted diseases.Am. J. Obstet.
Gynecol., 213(2):117, 2015.
[18] W. H. Organization. WHO guidelines for the treatment
of genital herpes simplex virus.World Health Organiza-
tion, 2016.
[19] S. R. Knox, L. Corey, H. A. Blough, and A. M. Lerner.
Historical findings in subjects from a high socioeconomic
group who have genital infections with herpes simplex
virus.Sex. Transm. Dis., 9(1):15–20, 1982

Article View: 16
PDF Download: 9